Patents by Inventor Vickie L. Brown-Driver

Vickie L. Brown-Driver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATION OF TRANSTHYRETIN EXPRESSION
    Publication number: 20220213474
    Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
    Type: Application
    Filed: August 9, 2021
    Publication date: July 7, 2022
    Inventors: Vickie L. Brown-Driver, Ravi Jain
  • MODULATION OF TRANSTHYRETIN EXPRESSION
    Publication number: 20180273949
    Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
    Type: Application
    Filed: November 3, 2017
    Publication date: September 27, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Vickie L. Brown-Driver, Ravi Jain
  • MODULATION OF TRANSTHYRETIN EXPRESSION
    Publication number: 20180179537
    Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 28, 2018
    Inventors: Vickie L. Brown-Driver, Ravi Jain
  • MODULATION OF TRANSTHYRETIN EXPRESSION
    Publication number: 20180179528
    Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 28, 2018
    Inventors: Vickie L. Brown-Driver, Ravi Jain
  • MODULATION OF TRANSTHYRETIN EXPRESSION
    Publication number: 20180179533
    Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 28, 2018
    Inventors: Vickie L. Brown-Driver, Ravi Jain
  • MODULATION OF TRANSTHYRETIN EXPRESSION
    Publication number: 20180179536
    Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 28, 2018
    Inventors: Vickie L. Brown-Driver, Ravi Jain
  • MODULATION OF TRANSTHYRETIN EXPRESSION
    Publication number: 20180179532
    Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 28, 2018
    Inventors: Vickie L. Brown-Driver, Ravi Jain
  • MODULATION OF TRANSTHYRETIN EXPRESSION
    Publication number: 20180179535
    Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 28, 2018
    Inventors: Vickie L. Brown-Driver, Ravi Jain
  • MODULATION OF TRANSTHYRETIN EXPRESSION
    Publication number: 20180179530
    Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 28, 2018
    Inventors: Vickie L. Brown-Driver, Ravi Jain
  • MODULATION OF TRANSTHYRETIN EXPRESSION
    Publication number: 20180179529
    Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 28, 2018
    Inventors: Vickie L. Brown-Driver, Ravi Jain
  • MODULATION OF TRANSTHYRETIN EXPRESSION
    Publication number: 20180179534
    Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 28, 2018
    Inventors: Vickie L. Brown-Driver, Ravi Jain
  • MODULATION OF TRANSTHYRETIN EXPRESSION
    Publication number: 20180179531
    Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 28, 2018
    Inventors: Vickie L. Brown-Driver, Ravi Jain
  • MODULATION OF TRANSTHYRETIN EXPRESSION
    Publication number: 20160348100
    Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
    Type: Application
    Filed: April 6, 2016
    Publication date: December 1, 2016
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Vickie L. Brown-Driver, Ravi Jain
  • MODULATION OF TRANSTHYRETIN EXPRESSION
    Publication number: 20150184157
    Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
    Type: Application
    Filed: February 5, 2015
    Publication date: July 2, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Vickie L. Brown-Driver, Ravi Jain
  • MODULATION OF TRANSTHYRETIN EXPRESSION
    Publication number: 20120149109
    Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
    Type: Application
    Filed: January 24, 2012
    Publication date: June 14, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Vickie L. Brown-Driver, Ravi Jain
  • Modulation of transthyretin expression
    Patent number: 8101743
    Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: January 24, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Vickie L. Brown-Driver, Ravi Jain
  • Antiviral Oligonucleotides Having a Conserved G4 Core Sequence
    Publication number: 20110124715
    Abstract: Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases are also provided.
    Type: Application
    Filed: August 4, 2010
    Publication date: May 26, 2011
    Inventors: Ronnie C. Hanecak, Kevin P. Anderson, C. Frank Bennett, Ming-Yi Chiang, Vickie L. Brown-Driver, David J. Ecker, Timothy Vickers, Jacqueline R. Wyatt
  • MODULATION OF TRANSTHYRETIN EXPRESSION
    Publication number: 20090082300
    Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
    Type: Application
    Filed: November 19, 2008
    Publication date: March 26, 2009
    Applicant: Isis Pharmaceuticals, Inc
    Inventors: Vickie L. Brown-Driver, Ravi Jain
  • Modulation of telomere length by oligonucleotides having a G-core sequence
    Patent number: 7067497
    Abstract: Modified oligonucleotides having a GGG motif sequence and a sufficient number of flanking nucleotides to modulate the telomere length of a chromosome are provided. Methods of modulating telomere length of a mammalian chromosome in vitro and in vivo are also provided, as are methods for inhibiting the division of a malignant mammalian cell and for modulating the effects of cellular aging.
    Type: Grant
    Filed: January 2, 2002
    Date of Patent: June 27, 2006
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Ronnie C. Hanecak, Kevin P. Anderson, C. Frank Bennett, Ming-Yi Chiang, Vickie L. Brown-Driver, David J. Ecker, Timothy A. Vickers, Jacqueline R. Wyatt
  • Antisense modulation of breast cancer-1 expression
    Publication number: 20040014051
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of breast cancer-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding breast cancer-1. Methods of using these compounds for modulation of breast cancer-1 expression and for treatment of diseases associated with expression of breast cancer-1 are provided.
    Type: Application
    Filed: July 18, 2002
    Publication date: January 22, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Vickie L. Brown-Driver, Kenneth W. Dobie